XML 105 R59.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Investments accounted for using the equity method (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Interests In Other Entities [Abstract] |
Summary of Investments in Associates and Joint Ventures |
(€ million) | % interest | 2023 | 2022 | 2021
EUROAPI(a) | 29.8 |  | 162 |  | 392 |  | — |
Infraserv GmbH & Co. Höchst KG(b) | 31.2 |  | 90 |  | 97 |  | 80 |
MSP Vaccine Company(c) | 50.0 |  | 96 |  | 104 |  | 88 |
Other investments | — |  | 76 |  | 84 |  | 82 |
Total |  | 424 |  | 677 |  | 250 |
(a) Following the distribution in kind and the acquisition of an equity interest by EPIC Bpifrance, Sanofi holds an equity interest in EUROAPI accounted for using the equity method in accordance with IAS 28 (see Note D.2.). As of December 31, 2023, an impairment loss of €231 million was recognized on the equity-accounted investment in EUROAPI in view of the fall in the share price since March 2023. The amount of the loss was determined on the basis of the share price as of December 31, 2023 (€5.73). (b) Joint venture. (c) Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.
Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures | The table below shows Sanofi’s overall share of (i) profit or loss and (ii) other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS 12 (the amounts for each individual associate or joint venture are not material):
| 2023 | 2022 | 2021 |
(€ million) | Joint ventures | Associates | Joint ventures | Associates | Joint ventures | Associates |
Share of profit/(loss) from investments accounted for using the equity method(a) | 101 |  | (216) |  | 74 |  | (6) |  | 26 |  | 13 |  |
Share of other comprehensive income from investments accounted for using the equity method | (7) |  | 8 |  | (2) |  | (3) |  | (6) |  | — |  |
Total | 94 |  | (208) |  | 72 |  | (9) |  | 20 |  | 13 |  |
(a) An impairment loss of €231 million was recognized on the equity-accounted interest in EUROAPI as of December 31, 2023, to reflect the fall in the share price since March 2023. The amount of the loss was determined on the basis of the quoted market price as of December 31, 2023 (€5.73).
Summary of Principal Transactions and Balances with Related Parties | The principal transactions and balances with related parties are summarized below:
(€ million) | 2023 |  |  | 2022 | (a) | 2021 |
Sales | 157 |  |  |  | 131 |  |  | 70 |  |
Royalties and other income | 63 |  |  |  | 81 |  |  | 66 |  |
Accounts receivable and other receivables(b) | 249 |  |  |  | 330 |  |  | 269 |  |
Purchases and other expenses (including research expenses) | 642 |  |  |  | 477 |  |  | 178 |  |
Accounts payable and other payables | 71 |  |  |  | 132 |  |  | 28 |  |
(a) In 2022, these items include Sanofi's transactions with EUROAPI from May 10, 2022 (see Note D.2.). (b) Includes loans to joint ventures and associates.

X
- Definition The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2023-01-01 -Paragraph 18 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of investments in associates and joint ventures explanatory. + References No definition available. + Details
Name: | sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of profit or loss and other comprehensive income of associates and joint ventures. + References No definition available. + Details
Name: | sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Interests In Other Entities [Abstract] + References No definition available. + Details
Name: | sny_InterestsInOtherEntitiesAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration